Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Food Effect and Cardiac Safety of Avacopan in Healthy Volunteers
NCT05988021Phase 1Completed
- Sponsor
- Amgen
- Start
- Dec 2015
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of avacopan in Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) (2 cohorts), sponsored by Amgen. Primary endpoints: Maximum Plasma Concentration up to 35 days, Time of Cmax up to 35 days and 2 more. Started Dec 2015; status: completed.
02
Drugs
avacopan
03
Conditions
Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)
Beyond the preview
Go deeper on NCT05988021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05988021.